Federated Hermes
QNCX icon

Federated Hermes’s Quince Therapeutics QNCX Stock Holding History

Federated Hermes’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4
Closed -$1.25K – 2206
2023
Q1 		$1.25K Sell
4
-1,248
-100% -$244K ﹤0.01% 2032
2022
Q4 		$160K Sell
1,252
-1,323
-51% -$221K ﹤0.01% 1593
2022
Q3 		$685K Sell
2,575
-68
-3% -$25.9K ﹤0.01% 1242
2022
Q2 		$1.17M Buy
2,643
+575
+28% +$406K ﹤0.01% 1084
2022
Q1 		$2.56M Buy
2,068
+1,537
+289% +$2.09M 0.01% 965
2021
Q4 		$1.34M Buy
531
+220
+71% +$1.34M ﹤0.01% 1169
2021
Q3 		$5.69M Buy
311
+153
+97% +$2.43M 0.01% 795
2021
Q2 		$1.68M Buy
+158
New +$1.32M ﹤0.01% 1149
2019
Q4 		– Hold
0
– -$2K – 2289
2019
Q3 		– Hold
0
– – – 2041

Other funds holding QNCX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KAM
Knightsbridge Asset Management Newport Beach, California $743M AUM 28.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes's QNCX Position: Q2 2023 in Review

Federated Hermes sold out of Quince Therapeutics (QNCX) in Q2 2023, closing a stake of 4 shares — an estimated $1.25K sold.

Federated Hermes first reported a position in QNCX in Q2 2021 and held it in 8 quarters. The position peaked at $5.69M in Q3 2021. 38 funds tracked by Wall St. Rank hold QNCX as of Q2 2023.

  • Federated Hermes reported no remaining Quince Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Federated Hermes sold 4 Quince Therapeutics shares in Q2 2023, an estimated $1.25K.
  • Federated Hermes first reported a position in Quince Therapeutics in Q2 2021 and held it in 8 quarters.
  • Federated Hermes's Quince Therapeutics position peaked at $5.69M in Q3 2021.
  • 38 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.